Back to Journal

Journal of Surgical Oncology & Clinical Research

Can be Seroma a normal event in Breast Surgery? Analysis from Survey in Plastic Surgery Safety Conference

[ ISSN : 3068-0727 ]

Abstract Citation Introduction Methods Results Discussion Conclusion References
Details

Received: 11-Aug-2017

Accepted: 14-Sep-2017

Published: 17-Sep-2017

Guillermo Ramos-Gallardo¹,², Carlos-Guillermo Oaxaca-Escobar¹, Jesus Cuenca Pardo¹, Livia Contreras-Bulnes¹, Eugenio Rodríguez-Olivares³, Imelda Díaz-Ruiz⁴, and Mauricio Alejandro García-López⁴*

¹Mexican Society of Plastic, Aesthetic and Reconstructive Surgery, Mexico
²Centro Universitario de la Costa, Universidad de Guadalajara, Mexico
³División Académica de Ciencias de la Salud, Universidad Juárez Autónoma de Tabasco, Mexico
?Hospital General de México, Mexico

Corresponding Author:

Guillermo Ramos-Gallardo, Av. Universidad de Guadalajara 203, Delegación Ixtapa, C.P. 48280, Puerto Vallarta, Jalisco, Mexico, Tel: 33-160261-81; Email: guiyermoramos@hotmail.com

Keywords

Breast implants; Breast augmentation surgery; Seroma

Abstract

Introduction: Breast Surgery especially augmentation is a common procedure worldwide. Literature reports relationship between chronic seroma and Anaplastic Large Cell Lymphoma (ALCL) has increased. Recently we reported the first case in Mexico. Risk factors should be evaluated. Seroma seems to be a common event after this type of surgery. Chronic seroma seems to be most common symptom in ALCL

Methods: Survey was conducted during Security Conference in breast implant augmentation, to know features as breast implants ratio in private practice of plastic surgeons, type of implant used, surgical technique and complications. Descriptive statistics including measures of central tendency were estimated.

Results: 72 members answered the survey. Implant placement is a procedure performed frequently. Preference is textured implants with volume between 300cc and 360cc. The most common complication was seroma. Reoperation was related with capsular contracture and patient no satisfaction.

Discussion: Seroma is a common complication. Possible relation with biofilm and Anaplastic Large Cell Lymphoma should be evaluated. Lymphoma is not a common finding in breast implant but long lasting infection can be considered as risk factor. Measures to prevent seroma should be proposed. Analysis from the type of textured in the coverage of the implant should be evaluated.

Conclusion: This information allows us to take further action to direct sessions, courses and conferences, to decrease the frequency of seroma and prevent complications being one of the procedures most frequently performed by the membership.

Citation

Ramos-Gallardo G, Oaxaca-Escobar CG, Cuenca-Pardo J, Contreras Bulnes L, Rodríguez-Olivares E, Díaz-Ruiz I, et al. Can be Seroma a normal event in Breast Surgery? Analysis from Survey in Plastic Surgery Safety Conference. J Surg Oncol Clin Res. 2017; 1(1): 1002.

Introduction

Breast implant surgery is a common procedure that has passed for different stages. It became one of the most common procedures worldwide [1]. It is important to know different information about preferences of surgical incision, pocket dissection, type of implant or common complications. Many conferences, articles and meeting have been organized about this topic. More information needs it in our population about this type of procedure.

Methods

A survey was conducted in the members of the Mexican Society of Plastic Surgery that participated in Security Conference during the International Meeting of our Society last February 26th, 2016 in Veracruz, México. The survey was multiple choice questions. The questionnaire addressed information as type of implant, surgical technique, complications and aspects about the professional practice and breast implants. All answers were collected with the help of Excel program. Descriptive statistics including measures of central tendency were calculated (Table 1).

Table 1: Survey about breast implants.

Survey

1.         What percentage of your practice occupy breast augmentation?

  1. 0 a 5 %.
  2. 6 a 10%.
  3. 11 a 20 %.
  4. Más del 20%.

2.         How much breast augmentation do you do at month?

  1. More than 1 at week.
  2. One per week.
  3. One every two weeks.
  4. One at month.

3.         What type of breast implant do you use more often?

  1. Rough
  2. Polyurethane
  3. Textured

4.         What is the shape that you prefer the most?

  1. Round
  2. Tear drop

5.         What type of profile do you use the most?

  1. Low
  2. Moderade
  3. High
  4. Extrahigh

6.         What is the most common surgical incisión?

  1. Periareolar
  2. Inframammary
  3. Axilar
  4. Umbilicus

7.         What plane do you use more often?

  1. Subglandular.
  2. Subfacial.
  3. Dual
  4. Submuscular

8.         What type of size do you use the most (volumen)?

  1. 200cc to 280cc.
  2. 300cc to 360cc.
  3. More than 360cc.

9.         What type of complication is the most common?

  1. Infection
  2. Seroma.
  3. Hematoma
  4. Implant exposure

10.        What is the most common cause of reoperation in breast augmentation?

  1. Assymetry
  2. Capsular contracture
  3. No satisfaction
  4. Rippling

11.        What is the frequency of reoperation in your practice?

  1. 0%.
  2. 1 to 5 %
  3. 6 to 10%
  4. 11 to 20%

12.        Have you seen any case of chronic seroma (more than one year after surgery)?

  1. Yes
  2. No

13.        Do you take in count anatomy of the thorax and breast tissue in your patients?

  1. Always
  2. Sometimes
  3. Never

14.        When you have a capsular contracture that cause pain and is clinically evident, what type of treatment do you recommend?

  1. Non surgical
  2. Capsulectomy
  3. Capsulotomy

Have you modified your practice when the meeting and conferences offered by the Security Commite?

  1. Yes
  2. No.
  3. Partially

15.        Have you notified complications or adverse event to our committe?

  1. Yes
  2. Sometimes
  3. No.

 

Results

Total of 72 members accepted to answer. No economical compensation was offered. About the percentage related with breast implants in their professional practice: 47% (34) answered that more of the 20% of the practice is related with breast augmentation, 29% (21) between 11 and 20%, 15% (11) between 6 and 10& and only 8% (6) less than 5%.

About the frequency of this type of procedure: 29% (21) do the procedure twice a month. 23% (17) once a month, 23% (17) once a week and 23% (17) more than one in a week. Most of the members prefer round implants 91% (66). Only 8% (6) prefer anatomical. About profile of the implant: 54 % (39) prefer high, 38% (27) extra high, 8% (6). Textured implant is most preferred with 86% (61),following rough 12% (9) and polyurethane 2%. Mostsurgeons guided the decisionin basis of the thorax and breast of the patient: 83% (59), 8% (6) never take in count and 9% (7) sometimes.

The range of volume that most of the surgeons preferred is from 300 to 360 with 62% (45), 14% (10) from 200 to 280 and 26% (17) more than 360.About the surgical incisión58% (42) preferedinframammary, 40% (29) periareolar and 2% axilar. The implant is located under the gland in 31%, under the fascia 26%, under the muscle 21% and dual plane 22%.About capsule contracture 51% (37) remove capsule (capsulectomy), 36% (26) capsulotomy, 12% (9) prefer non-surgical treatment. Most common complication is seroma 68% (49), hematoma 15% (11), implant extrusion 11% (8) and infection 5% (4).

Most of the surgical reoperation was related with capsule 55% (40), patient no satisfaction 15% (11), asymmetry 8% (6), rippling 4% (3).

Taking in count reoperation: 72% (52) mentioned that rate of reoperation was between 1 to 5%, 5% (4) between 6 to 10%, 8% (6) report more than 20% of reoperation and 14% (10) reported no reoperations. 52% (35) of the participants have modified their surgical approach and clinical practice related with the information discussed by the Security Committee and 20% (14) have modified in a partial way. Most of our members have not notified their complications 72% (49).

Discussion

The decision about breast implant size, position, type or shape depends of many variable that take in count the body of the patient and sometimes cannot satisfied her expectations [2]. The thorax and breast tissue of patients in Mexico is different from other parts of the world as USA or Europe. Although patient can be different most of the surgeons prefer size between 300 or 360 cc, probably bigger size than 360 in our population can contribute reoperation and malposition in long term.

Periareolar incision was an important choice according with results from the Survey. Literature benefit inframmamary incision and texture implants [3-5].

Most of the members report high rate of seroma. Seroma can be involved in biofilm formation [6]. Biofilm holds bacteria that can be related with capsule contracture [7]. Some type of bacteria is reported in cases with Anaplastic Large Cell Lymphoma [8]. Not all the patients with seroma will develop this problem but it is important to mention that the possible links have been reported and risk factors and possible cause are under research [9]. In a bigger on line survey in 2014from 340 participants, 64% (191) mentioned that the most common complications were seroma.

It is not clear if seroma can be considered a normal event in the early posoperative period. Seroma has been study in breast surgery especially after mastectomy combined with node dissection. It is recognized that surgical trauma can increased it, probably with over use of cauterization and aggressive surgery with excessive blood lost [10].

More information is needed about seroma prevention. Drains are possible solution. Infection risk should be evaluated. Routine drainage in breast augmentation can be considered for two or three days [1,11].

The risk of infection can be decreased as in any surgery with the help of simple measures as hand washing, keeping clean surgical incisions and coverage with clean gauze. Antibiotics can help to decrease biofilm formation although is not clear timing and duration [1,6,7].

In case of implant exposure it is recommendable to consider removal of the implant. It is a doubt if small exposure can be closed in the office with proper care. Evidence doesn´t support this believe [10,11]. Expert agrees to try it, if patient conditions are satisfied as healthy patient and clean surgical incision.

In the other hand most of the surgeons are not comfortable using fat graft in aesthetic procedure. In reconstructive surgery is not a doubt about the possible benefit. Probably in aesthetic surgery calcification can difficult cancer screening [12-14]. In case of capsular contracture it is recommendable to remove capsule and to use different plane [15]. Survey shows no agreement in this matter. Surgeons can try less aggressive treatment at the begging without addressing original trouble.

Reoperation in breast implant it can be related with different reasons as for example capsular contracture, ptosis or ripling. Lifespan of breast implant is confusing matter [16]. Companies can make information about life guaranteed but patient should be informed about possible implant rupture, chronic seroma, ptosis or capsular contracture [17]. Informed consent should mention that replacement should be considered, timing can be around 14 to 15 years. Regular control with physician is advisable.

Capsular contracture, pain or rippling should be considered when replacement is evaluated. Surgical plan can considered change of plane or additional procedure as dermal matrices [18,19]. Cancer screening should be emphasizes, regular mammogram or ultrasound should be encourage no matter breast implant location or size.

Seroma was the most common complication. It is not clear what the best evidence to decrease this problem is? Antibiotics and use of drains can get some benefit. As we know bacteria can life for long time in the biofilm, and seroma can predispose this condition. Chronic seroma has been involved in ALCL [20]. We are not sure if both condition: acute or chronic seroma share the same etiology or they are same problem with different stage. Carefully planning and meticulous surgical technique are important to decrease morbidity, reoperation and patient satisfaction.

Conclusion

Breast implant surgery is a common procedure. Texture implants have become important choice. Size from 300–360, round, high and extra high profile, surgical incision in the lower inframmamary border and placement under the muscle are common preferences in the survey. Seroma was the most common complication. Future directions to identify and treat acute and chronic seroma should be proposed. Acute seroma can be associated with biofilm. It is not clear the etiology of conditions as ALCL. This information allows us to take further action to direct sessions, courses and conferences, to decrease the frequency of seroma and prevent complications being one of the procedures most frequently performed by the membership.

References

1. Cuenca-Pardo J, Ramos-Gallardo G, Contreras-Bulnes, Iribarren-Moreno R, Rodríguez Olivares E, Hernández-Valverde C, et al. Factores relacionados con las infecciones en implantes mamarios. Encuesta a miembros de la Asociación Mexicana de Cirugía Plástica Estética y Reconstructiva. Cirugía Plástica. 2015; 25: 6 -14.

2. Vallarta-Rodríguez RA, Ruiz-Treviño JJ, Guerrero-Burgos F. Mamoplastia de aumento dinámica con control de vectores. CirplastIberolatinoam. 2014; 40: 377-384.

3. Colombo C, Flores Z. Revisión a 5 años de técnicas quirúrgicas y características de los implantes en 2876 mamoplastías de aumento consecutivas. CirplástIberolatinoam. 2015; 4: 219-233.

4. Lista F, Ahmad J. Evidence-Based Medicine: Augmentation Mammaplasty. PRS. 2013; 132: 1684-1696.

5. Liu X, Zhou L, Pan F, Gao Y, Dongli F. Comparison of the Postoperative Incidence Rate of Capsular Contracture among Different Breast Implants: A Cumulative Meta-Analysis. Plos One. 2015; 13: 1-18.

6. Ramos-Gallardo G. Chronic Wounds in Burn Injury: A Case Report on Importance of Biofilms. WJPS. 2016; 5: 175-179.

7. Ramos-Gallardo G. How I Can Suspect of Mycobacteria Infection in Breast Implant Surgery? WJPS. 2016; 5: 2-5.

8. Ramos-Gallardo G, Cuenca-Pardo J, Contreras-Bulnes, Iribarren-Moreno R, Rodríguez Olivares E, Hernández-Valverde C, et al. Breast Implant and Anaplastic Large Cell Lymphoma Meta-Analysis. Journal of Investigative Surgery. 2017; 30: 56-65.

9. Torres-Rivero, Ramos-Gallardo, Nambo-Lucio, Vaquero-Pérez MM. Primer caso en México y América Latina de linfoma anaplásico de células gigantes en paciente con implantes mamarios. CirugíaPlásticaIbero-Latinoamericana. 2016; 42: 175-180.

10. Bengtson B, Brody G, Brown M, Glicksman C, Hammond D, Kaplan H cols. Managing Late Periprosthetic Fluid Collections (seroma) in Patients with Breast Implants: A consensus Panel Recomendation and Review of the Literature. PRS. 2011; 128: 1-7.

11. Derby BM, Codner MA. Textured Silicone Breast Implant Use in Primary Augmentation: Core Data Update and Review. PRS. 2015; 135: 113-124.

12. Gurunluoglu R, Bronsert M. A comparative analysis of 2 Nationals Breast Reconstruction Surveys: Concern Regarding Autologous and Microsurgical Breast Reconstruction. PRS Global. 2014; 1-4.

13. Negrete-Hernández S, Barba-Gómez J, Magallanes-Negrete E, Audelo-Aun C. Aumento mamario estético con transferencia de tejido graso autologo sin expansión previa. CirplastIberolatinoam. 2013; 39s: 58-64.

14. Kling RF, Mehrara B, Pusic A, Young L, Hume K, Crotty C, Rubin P. Trends in Autologous Fat Grafting to the Breast: A National Survey of the American Society of Plastic Surgery. PRS. 2013; 132: 35- 46.

15. Hannah Headon, et al. Capsular contracture after breast augmentation an update for clinical practice. Archives of Plastic Surgery. 2015; 42: 532-543.

16. Cardenas-Camarena L, Chung-Gallardo J, Echeverria-Rolda G, Leon MA, Oaxaca-Escobar C, García-Fabian F. Estudio multicéntrico prospectivo observacional sobre implantes PIP colocados en 12 años. CirplastIberolatinoam. 2014; 40: 385-393.

17. Maxwell P, Allen G. The Evolution of Breast Implants. PRS. 2014; 134: 12s-17s.

18. GoulartJr R, Onida Matos M. Implantes mamarios y mastopexia colgajos mamarios laterales y mediales una opción técnica. CirplastIberolatinoam. 2012; 38: 313-321.

19. Khavanin N, Jorda SW, Rambachan A, Kim JY. A systematic Review of Single-Stage Augmentation-Mastopexy. PRS. 2014; 134: 922-931.

20. Miranda RN, Aladily TN, Prince HM, Rashmi KS, de Jong D, Fayad LE y cols. Breast Implant Associated Anaplastic Large Cell Lymphoma: Long Term Follow up of 60 patients. Journal of ClinicalOncology. 2014; 32: 114-120.

Other Articles

Article Image 1

Merkel Cell Carcinoma of the Inguinal Lymph Node in the Absence of a Primary Site: A New Case Report and Literature Review

Introduction: Merkel Cell Carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. The main characteristics are frequent local recurrences and disseminations to regional lymph nodes and distant organs. MCC within the lymph nodes in the absence of a primary site is rare and few cases have been reported by the literature.

Case Report: We report a case of MCC presenting as a painless mass in the left inguinal area for 6 months in a 48-year-old women. The histopathology of the excised lesion revealed a poorly differentiated basophilic small cell tumor. The immunohistochemical study finding the diagnosis of a metastatic MCC. Despite extensive clinical and radiological investigation, we failed to identify the origin of the tumor.

Conclusion: Rare cases of MCC confined to a lymph node without an apparent primary site have been reported. We report a new case of MCC in the inguinal lymph node without identification of the primary site.

Mohamed Amine Azami¹, Othman Lahbali¹, Iliass El Alami², Zouidia F¹, and Mahassini N¹*


Article Image 1

Percentage of Surgical Lung Cancers Missed by National Screening Criteria

Background: The US Preventive Services Task Force (USPSTF) recommends screening for smokers based on age, pack-years of smoking, and years since past smokers quit (quit-time). Previous studies determined low dose computerized tomography (LDCT) to be the best method, but have not identified the population at highest risk. This study sought the percentage of lung cancer patients that would have been excluded by USPSTF criteria.

Method: A retrospective chart review identified 170past and present smokers who had undergone lung cancer resection at Hackensack Meridian Health (HMH) hospitals between September 15, 2014 and 2016. Data was collected from the Society of Thoracic Surgeons database. Descriptive statistics and Wilcoxon Rank-Sum tests were used to analyze differences between included and excluded patients.

Results: The percentage of patients that would have been excluded by screening criteria was 46.5% (95% CI: 38.8-54.3%). The difference between ages of included and excluded patients was not quite significant (p=0.051), with only17.1% (95% CI: 11.7-23.6%) of all patients excluded by age. Pack-years of included patients were significantly higher than of the excluded (p<0.001), and 25.3% (95% CI: 18.9-32.6%) had insufficient pack years. Quit-time was also a significant variable (p<0.001) and excluded 37.9% (95% CI: 29.1-49.4%) of past smokers. The percentage included by USPSTF criteria increased from 53.5% to 59.4% when quit-time was set to 25 years, and61.2% when extended to 30 years.

Conclusion: USPSTF criteria would have excluded almost half of the ever-smokers with surgically resectable lung cancers. Age would not have excluded a significant percentage, but inclusion criteria should account for smokers with less than 30 pack-years or who quit over 15 years ago. Future reviews should examine screening efficacy in larger databases. Prospective studies should investigate correlation between age and smoking history, and look to include secondhand smoking and occupational exposure as risk factors for screening.

Hannah A Lee¹, Asa Dewan MS², Kelly Rubino BSN³, Mila Lachica BA¹,², Arthur A Topilow⁴ and Thomas L Bauer³*


Article Image 1

Case Report: Vigil Therapy in Pathology Defined High-Risk Differentiated Thyroid Cancer Compounded by Post Ablation High-Risk Factors

Thyroglobulin levels ≥50 μg/L following thyroidectomy and I131 ablation correlate with poor prognosis in patients with high risk Differentiated Thyroid Cancer (DTC). We describe a case of a 54 year old woman with differentiated thyroid cancer and high thyroglobulin up to 220 μg/L following thyroidectomy and I131 ablation who demonstrated marked response to a novel immunotherapy involving autologous tumor cell transfected with a GMCSF/bi-shRNA furin expressive plasmid (Vigil). Activity is highlighted by four year disease free survival in correlation with immune activation as measured by ELISPOT assay of peripheral blood mononuclear cell reaction to autologous tumor. Further investigation with Vigil in differentiated thyroid cancer is warranted.

Minal Barve¹,², Radhika Barve¹, Jennifer Rao¹, Luisa Manning³, Donald D Rao⁴, Ned Adams¹, Neil Senzer¹,³,⁴ and John Nemunaitis¹-⁵*



Article Image 1

Role of Pre -Treatment FDG PET Quantitative Parameters in Prognostication of Head and Neck Squamous Cell Carcinoma - A Review

In spite of the good organ preservation strategies available for locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC), failure rates have been reported to be as high as 35-50%. There has been an increasing interest in predicting response to treatment, to aid early intervention and better outcomes. FDG-PET is a standard modality for post treatment evaluation, however it is still under utilized as a pre-treatment investigative modality. Several articles have described quantitative parameters in pre-treatment FDG-PET to prognosticate patients and determine likelihood of response to treatment however they are still not used commonly. This article was a review of the literature available on pre-treatment FDG PET quantitative parameters and their value in predicting failure. A thorough review of literature from MEDLINE and EMBASE was performed on pre treatment quantitative parameters in HNSCC. Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) were reliable parameters to predict response to organ preservation therapy, disease free and overall survival. SUVmax was an inconsistent parameter. MTV and TLG may help predict poor response to organ preservation to initiate early surgical salvage or modify therapeutic decisions to optimize clinical outcomes. Routine incorporation into PET reporting may provide additional information over SUVmax alone.

Narayana Subramaniam, Deepak Balasubramanian*, Shanmuga Sundaram P and Samskruthi Murthy 


Article Image 1

Staged Surgery Combined with Chemo Radiation Improves Outcome after Incomplete Removal of Gallbladder Cancer

Introduction: Gallbladder carcinoma is the most frequent tumor of the bile system and has a poor prognosis. The main proportion of tumors diagnosed coincidentally after gallbladder removal for various reasons. In these cases, an incomplete removal of the tumors occurs frequently. The adequate treatment of these patients is still under discussion. We present our experience with different procedures.

Patients and Methods: Between 1990 and 2015, we identified 20 patients which were presented at our University Hospital after incomplete removal of gallbladder cancer (R1, R2, RX) as incidental findings after cholecystectomy. The prospectively collected data including surgery, adjuvant treatment, histopathological examinations of the specimens and follow-up data were analyzed retrospectively.

Results: The median age of patients was 72 years (range 47-89 years), 90 % (18/20) were female. The median follow-up period was 10 months (range 0-109 months). The median survival of all patients was 11 months (95 % confidence interval: 5-17 months). The median survival of patients who received staged surgery and chemo radiation after incomplete gallbladder removal was significantly increased (median 32 months; range 4-109 months) vs. patients who received chemo radiation without surgery (median 13 months; range 8-51 months) or chemotherapy alone (median 2.5 months (range 0-40 months)) (p = 0.005).

Discussion: There is no standardized treatment for residual tumor after incomplete gallbladder cancer resection. Our data demonstrate that staged surgery with prior chemo radiation may improve patient´s outcome. Surgery can be performed with low morbidity and mortality.

Marc Daniels¹, Maximilian Brunner¹, Sabine Semrau², Robert Grützmann¹ and Roland S Croner¹*


Article Image 1

Limb Salvage in Patients with Unresectable Recurrent Melanoma and Sarcoma with the Hyperthermic Isolated Limb Perfusion Technique

Introduction: Hyperthermic Isolated Limb Perfusion (HILP) is a surgical procedure for the regional delivery of heat and high doses of chemotherapy and biologic agents to the extremity. The procedure is employed as a limb salvage technique for locally advanced primary malignancies or recurrent cancers that are unresectable and confined to the extremity

Methods: From 1987-2016, 247 patients with unresectable recurrent melanoma (95%), sarcoma or Merkel Cell Carcinoma underwent HILP for limb salvage of the affected extremity after staging was negative for Stage IV disease and disease was confirmed to be confined to the extremity.

Results: All patients had limb salvage with this protocol. All patients were clinically negative in their regional basin at the time of perfusion, although 40% of the patients had evidence of regional nodal disease following nodal dissections. Immediate responses (within 3 months) on the extremity to the HILP were as follows: complete response (CR) of 66%, partial response (PR) of 20%, 10% stable disease and 4% progressive disease. With a mean follow-up period of 5 years, 61.5% of the patients have recurred with 68.4% of the recurrences being systemic, 21% regional nodal, 7.2% in-transit and 3.3% local-regional soft tissue.

Conclusions: HILP is an effective strategy for limb salvage in patients with unresectable, locally advanced cancers confined to the extremity. The treatment was associated with a high rate of complete responses on the extremity. Most patients recurred with distant metastases emphasizing the need for better systemic therapies for these malignancies.

Synopsis: Patients with recurrent, unresectable melanoma, other cutaneous malignancies and sarcoma confined to an extremity are problematic for clinicians since recurrence rates show that most will have occult systemic disease. An aggressive amputation approach does not make sense and the fact that these patients have active disease makes them ineligible for approved adjuvant therapies. In addition since their clinically apparent active disease is confined to the local/regional soft tissues making them Stage 3 disease, they are not eligible for Stage IV protocols. In these situations Hyperthermic Isolated Limb Perfusion (HILP) effectively treats the extremity with high response rates and a 100% limb salvage rate.

Lauren Kerivan, Michael Reintgen, Eric Reintgen, Steve Shivers and Douglas Reintgen* 


Article Image 1

Self-related Quality of Life and Functional Results after Internal and External Hemipelvectomy in 82 Musculoskeletal Pelvic Tumours

Background and purpose: Wide resection in pelvis delivers important drawbacks not only physically but also mentally lowering the functional status and self-related quality of life (SRQL) of these patients. Our aim is to show functional results and SRQL in patients with wide resections in pelvis due to musculoskeletal tumours.

Patients and Methods: It is a retrospective study in patients with wide resections in pelvis due to musculoskeletal tumours and we focus on: demographical data, preoperative and pathology studies, type of resection and reconstruction, functional results (MSTS score) and SRQL (SF-12). We have performed 15 external hemipelvectomies (EH), 57 internal hemipelvectomies with pelvic ring stability reconstruction (IHPR), 10 internal hemipelvectomies without reconstruction of the pelvic stability (IHWR). There were 10 patients with soft tissue sarcomas and benign but aggressive tumours that we do not include in the study as they did not need hemipelvectomy.

Results: We found there is a tendency to better functional results in IHPR, though it shows no statistical differences between the three types of reconstruction. According to SRQL we observed light score loss in mental status related to general population. On the other hand, physical status showed strong score deviation from general population. Functional results seem to be similar to literature.

Interpretation: The severe loss of function and physical status in these patients underline the type reconstruction and avoiding complications as critical steps. The light score deviation in mental status may represent an adaptive pattern and social support of patients with this severe disease and its complications.

Pérez-Muñoz Israel*


Article Image 1

Alveolar Soft Part Sarcoma: Case Report of a Rare Tumor and Review of Literature

Alveolar soft part sarcoma (ASPS) is a rare neoplasm occurring most frequently in the soft tissues of both children and adults, which has a tendency for an indolent course and late metastasis. It is characterized by an unbalanced translocation, der(17)t(X:17)(p11;p25), producing a fusion protein which has recently been shown to play a role in promoting cell proliferation and angiogenesis and may provide a potential target for molecular therapy. We present a case of ASPS and discuss the histology, diagnostic considerations, cytogenetics, treatment, and prognosis.

Glyn Hinnenkamp*, Amy Hackett, Brandon Grodman, Logan Primeaux , Ashley Green, Savannah Sadaiappen , Sylvester Bote, and Mohamed Aziz 


Article Image 1

Secondary primary common bile duct neuroendocrine tumor 10 years after the diagnosis of rectal adenocarcinoma: A case report

Development of a second primary cancer in patients under follow-up because of metastasis is rare. We presented a 58-year-old man with neuroendocrine cancer of vater ampulla and distal common bile duct as a second primary cancer. The patient had been diagnosed with rectal adenocarcinoma and lung metastasis who underwent total mesorectal excision, lung lobectomy, and adjuvant therapy with an interval of 5 years. This article emphasizes on the importance of early detection of second primary cancer and treating it as the primary one

Saba Ebrahimian MD, Sakineh Soleimani Varaki MD 


Article Image 1

Metastatic Chordoma to the lung. Case Report of a Rare Tumor and Brief Review of the Literature

Chordomas are rare, malignant bone tumors with a typically unfavorable prognosis that develop slowly and aggressively along the skull base and axial skeleton from remnants of the primitive notochord. Grossly, chordomas classically present as lobular nodules with thick fibrous tissue; histologically, those fibrous tissues can be seen separating chords of tumor cells in a myxoid stroma. Its characteristic local aggressiveness and indolent growth makes timely detection difficult and local recurrence likely, especially since surgical resection and radiation are the only affective treatment options. Local recurrence currently serves as a significant predictor of metastatic progression which most commonly involves the lungs, liver, bone, and lymph nodes. We report a case of metastatic chordoma to the lung, and discuss the diagnostic features, differential diagnosis, molecular changes, treatment, and prognosis.

Bryan Neal*, Sidney Nathan, Adam Hebert, Clifford Davis, Jodie Simelda, Anthony Dean, Gevork Seifert, Mohamed Aziz